04:08:47 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-27 Ordinarie utdelning SOFTX 0.00 NOK
2024-06-26 Årsstämma 2024
2024-05-29 Kvartalsrapport 2024-Q1
2024-03-27 Extra Bolagsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 Ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2019-01-04 17:58:28
Reference is made to the stock exchange release by SoftOx Solutions AS (the
“Company” or “SoftOx” with Merkur ticker: “SOFTOX-ME”) on 21 December 2018
regarding successful private placement (the “Private Placement”) of new shares
in the Company.

SoftOx is pleased to announce that the Company has successfully completed a NOK
15 million Private Placement with the support from new and existing
shareholders. In addition, the general assembly held at the 2nd, of January
2019, accepted additional private placement of NOK 3,162 million ending at a
total of NOK 18.162.100. The Private Placement consists of 825 550 new shares,
each at a subscription price of NOK 22.

The following primary insiders of the Company have been conditionally allocated
shares in the Private Placement:

•	Hermod Finans AS, a company fully owned by an affiliate of Geir
Almås, Chief Executive Officer: 91,000 shares. Geir Almås and affiliates
controls after the share issue 788,750 shares.
•	Dinge Invest AS, a company fully owned by Kristian Almås and family,
Non-executive member of the Board: 286.805 shares. Kristian Almås and affiliates
controls after the share issue 1,641,755 shares, after a post issue adjustment
of 59.850 sold for NOK 22 per share reported January 4th.
•	Loyd AS, a company fully owned by Lars Johan Frigstad, Chairman of the board:
16,000
shares. Lars Johan Frigstad controls after the share issue 135.250 shares.
•	Glenn Gundersen, Director Medical Affairs: 7,500 shares. Glenn Gundersen
controls after the 
share issue 15,000 shares.

Completion of the Private Placement is conditional upon the Offer Shares having
been fully paid and legally issued. Following issuance of the Offer Shares, the
Company will have an issued share capital of NOK 92 084 divided into 4,604,200
common shares, each with a nominal value of NOK 0,02.

SpareBank 1 Markets AS acted as manager in the Private Placement. 

For further information, please contact:
Mr. Geir H. Almås, CEO, tel: +47 977 59 071, e-mail:
geir.almaas@soft-ox.com